Bright Minds Biosciences Inc.: Form 20-F for the period ended Sep 30, 2023
Filed with the SEC on Dec 29, 2023 and accepted by EDGAR at Dec 29, 2023, 16:30 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Income tax | 12 months2022-10-01 to 2023-09-30 | CAD 0 | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2022-10-01 to 2023-09-30 | −CAD 7.4m | ifrs-full:ProfitLoss |
| Diluted EPS | 12 months2022-10-01 to 2023-09-30 | −CAD 1.98 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2022-10-01 to 2023-09-30 | −CAD 1.98 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2022-10-01 to 2023-09-30 | −CAD 7.0m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Cash and equivalents | At period end2023-09-30 | CAD 6.7m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2023-09-30 | CAD 6.8m | ifrs-full:CurrentAssets |
| Total assets | At period end2023-09-30 | CAD 6.9m | ifrs-full:Assets |
| Current liabilities | At period end2023-09-30 | CAD 280.9k | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2023-09-30 | CAD 280.9k | ifrs-full:Liabilities |
| Shareholders' equity | At period end2023-09-30 | CAD 6.6m | ifrs-full:Equity |
| Shares outstanding | At period end2023-09-30 | 4,463,837 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001062993-23-023281. Last ingested by Listed: Nov 2, 2026, 18:24 ET. Listed shows no prices and gives no investment advice.